@misc{oai:repo.qst.go.jp:00085932,
 author = {李, 惠子 and 安康, 真由香 and 長谷川, 純崇 and Li, Huizi and Mayuka, Anko and Sumitaka, Hasegawa},
 month = {Sep},
 note = {Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. Peritoneal metastasis is one of the common metastases of USC. Although trastuzumab, the anti-HER2 antibody, has shown benefit in the treatment of HER2 positive USC, the therapeutic efficacy is still limited. 
Antibody drug has been employed as the therapeutic option for cancer and provided benefits, however the acquired resistance of antibody-drug has been challenges to overcome for cancer treatment.
Targeted alpha therapy (TAT) has high potential as a promising therapeutic option for metastasis. Astatine 211 (At-211) is one of the attractive α-particle emitters with an appropriate half-life and producible with cyclotron. We have demonstrated experimental TAT using [At-211]trastuzumab to preclinical mouse model with peritoneal metastasis of HER2 positive USC in order to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for antibody drug resistant peritoneal metastasis of HER2 positive USC., 日本放射線影響学会第64回大会},
 title = {抗体薬抵抗性子宮体部漿液性がん腹膜播種に対する標的アルファ線治療},
 year = {2021}
}